Home › Funds › FOSTER DYKEMA CABOT & PARTNERS, LLC › VRTX
FOSTER DYKEMA CABOT & PARTNERS, LLC position in VRTX
VERTEX PHARMACEUTICALS INC · Health Care
FOSTER DYKEMA CABOT & PARTNERS, LLC reported holding 56,939 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$29.8M, representing 1.57% of its reported portfolio and ranking #17 among its reported holdings. FOSTER DYKEMA CABOT & PARTNERS, LLC has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
Last updated: 2026-10-31 · Source: SEC EDGAR Form 13F-HR
How FOSTER DYKEMA CABOT & PARTNERS, LLC's VRTX position evolved
FOSTER DYKEMA CABOT & PARTNERS, LLC first disclosed a stake in VRTX in Q4 2023 at 57,426 shares (US$23.4M). The position peaked in Q1 2025 at 61,455 shares, worth US$29.8M. Across 12 filings, FOSTER DYKEMA CABOT & PARTNERS, LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 56,939 shares valued at US$29.8M — a reduction of -1,294 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 57.43K | $23.37M | New |
| Q1 2024 | 59.73K | $24.97M | Add |
| Q2 2024 | 59.98K | $28.11M | Hold |
| Q3 2024 | 59.77K | $27.80M | Hold |
| Q4 2024 | 60.86K | $24.51M | Add |
| Q1 2025 | 61.45K | $29.79M | Add |
| Q2 2025 | 60.92K | $27.12M | Reduce |
| Q3 2025 | 60.69K | $23.77M | Hold |
| Q4 2025 | 58.34K | $26.45M | Reduce |
| Q1 2026 | 57.79K | $25.81M | Reduce |
| Q2 2026 | 58.23K | $28.93M | Add |
| Q3 2026 | 56.94K | $29.77M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VRTX and 13F data
VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRTX
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital World Investors 26.12M sh · $12.97B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Capital Research Global Investors 19.49M sh · $9.68B · Q2 2026
- Invesco Ltd 8.04M sh · $4.00B · Q2 2026
- LOOMIS SAYLES & CO L P 3.92M sh · $1.95B · Q2 2026
- JENNISON ASSOCIATES LLC 3.00M sh · $1.49B · Q2 2026
- ALLIANCEBERNSTEIN L.P. 3.02M sh · $1.35B · Q2 2026
- Clearbridge Investments, LLC 2.34M sh · $1.16B · Q2 2026
- VICTORY CAPITAL MANAGEMENT INC 2.17M sh · $1.08B · Q2 2026
- Janus Henderson Group 2.13M sh · $951.79M · Q1 2026
More on FOSTER DYKEMA CABOT & PARTNERS, LLC
FAQ
How long has FOSTER DYKEMA CABOT & PARTNERS, LLC held VRTX?
FOSTER DYKEMA CABOT & PARTNERS, LLC has disclosed VRTX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.
What is FOSTER DYKEMA CABOT & PARTNERS, LLC's current position in VRTX?
As of Q3 2026, FOSTER DYKEMA CABOT & PARTNERS, LLC holds 56.94K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $29.77M, representing 1.57% of its reported portfolio and ranking #17.
Has FOSTER DYKEMA CABOT & PARTNERS, LLC been buying or selling VRTX?
In the latest 13F filing (Q3 2026), FOSTER DYKEMA CABOT & PARTNERS, LLC reduced its position in VRTX. The position peaked in Q1 2025 at 61.45K shares.
Which other funds hold VRTX?
Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.